An open-label, nonrandomized, crossover study to evaluate the safety, efficacy and pharmacokinetics of Ponatinib alone and in combination with Rifampin in healthy volunteers

Trial Profile

An open-label, nonrandomized, crossover study to evaluate the safety, efficacy and pharmacokinetics of Ponatinib alone and in combination with Rifampin in healthy volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Oct 2015

At a glance

  • Drugs Ponatinib (Primary) ; Rifampicin
  • Indications Acute lymphoblastic leukaemia; Chronic myeloid leukaemia
  • Focus Pharmacokinetics
  • Sponsors ARIAD Pharmaceuticals
  • Most Recent Events

    • 29 Oct 2015 New trial record
    • 01 Sep 2015 Results were published in Clinical Pharmacology in Drug Development.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top